Guidelines issued by DoP for bulk drug parks

A brief guidelines for bulk drug parks and detailed guidelines will be released soon by
The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilisers, the Government of India. DoP has also announced the details of a financial assistance programme which includes grant-in-aid to three bulk drug parks with a total incentive of Rs 3000 crores for the construction of common infrastructure facilities.
Implementation of the proposed scheme will be done through a one time grant in aid and will be released in various phases for the creation of infrastructure in bulk drug to a State Implementing Agency.

The particular programme has a proposal to provide grant-in-aid to three bulk drug parks with a maximum limit of Rs 1000 crores per bulk drug park or 70 per cent of the project cost of common infrastructure facilities, as per the issued notification by Navdeep Rinwa, Joint Secretary, Department of Pharmaceuticals, .

The same notification also states that that in case of hilly regions and the North East Region, the grant-in-aid would be Rs 1000 crore per bulk drug park or 90 per cent of the project cost of common infrastructure facilities, whichever is less.

The proposed scheme would be helpful for infrastructure facilities like solvent recovery, distillation plant, central effluent treatment plant, common logistics facilities, advanced common testing centre, regulatory awareness facility centre, emergency response centre etc.

“We welcome the issued brief guidelines on bulk drug parks. The Himachal Pradesh Government is very keen on setting up the bulk drug park in the State with the help of the announced scheme by the Central Government. The State government is planning to acquire approximately 1350 acres of land, it has already identified 1000 bigha land and will be exploring the possibilities to acquire more land.” Dr Rajesh Gupta, a member of the Bulk Drug Park Committee, Himachal Pradesh and President, Himachal Drug Manufacturers Association (HDMA) told.

“We are reviewing the guidelines and will be discussing with the state industrial bodies.” said Ritu Sahay, Director-Drugs Controller, Jharkhand.

The proposal for application will be open from 2020-2021 to 2024-2025.

  • Related Posts

    Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

    New Delhi:  The Supreme Court on Friday (March 13, 2026) refused to direct the government to compulsorily conduct “expensive” Nucleic Acid Tests (NAT) to identify diseases ahead of blood transfusions,…

    Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

    Jaipur— Brahmpuri police in Jaipur have arrested a notorious fraudster who systematically extorted money from medical store owners by impersonating a Drug Inspector. The same accused, Arun Kumar, also cheated…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

    Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

    Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

    Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

    India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

    India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Top 30 pharma companies post 12% revenue growth in first nine months

    Top 30 pharma companies post 12% revenue growth in first nine months

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory